Back to top
more

Actinium Pharmaceuticals (ATNM)

(Delayed Data from AMEX)

$6.87 USD

6.87
206,378

+0.31 (4.73%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $6.89 +0.02 (0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Company Summary

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for their ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With their ARC approach, they seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Their lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SI

General Information

Actinium Pharmaceuticals, Inc

100 Park Ave. 23rd Floor

NEW YORK, NY 10017

Phone: 646-677-3870

Fax: NA

Web: http://www.actiniumpharma.com

Email: investorrelations@actiniumpharma.com

Industry Medical - Drugs
Sector Medical
Fiscal Year End December
Last Reported Quarter 3/31/2024
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 5/20/2024

EPS Information

Current Quarter EPS Consensus Estimate -0.42
Current Year EPS Consensus Estimate -1.87
Estimated Long-Term EPS Growth Rate NA
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 5/20/2024

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 6.56
52 Week High 9.86
52 Week Low 4.00
Beta 0.01
20 Day Moving Average 331,934.19
Target Price Consensus 25.72

ATNM

% Price Change
4 Week -12.26
12 Week 29.62
YTD 35.24
% Price Change Relative to S&P 500
4 Week -9.60
12 Week 26.03
YTD 22.01
Share Information
Shares Outstanding (millions) 29.40
Market Capitalization (millions) 201.95
Short Ratio NA
Last Split Date 8/11/2020
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year 21.43%
vs. Previous Quarter 32.65%
   
Sales Growth
vs. Previous Year NA%
vs. Previous Quarter NA%
   
Price Ratios
Price/Book 5.24
Price/Cash Flow NA
Price / Sales NA
ROE
3/31/24 NA
12/31/23 -102.64
9/30/23 -91.02
ROA
3/31/24 NA
12/31/23 -52.57
9/30/23 -49.62
Current Ratio
3/31/24 NA
12/31/23 9.21
9/30/23 9.87
Quick Ratio
3/31/24 NA
12/31/23 9.21
9/30/23 9.87
Operating Margin
3/31/24 NA
12/31/23 NA
9/30/23 NA
Net Margin
3/31/24 NA
12/31/23 NA
9/30/23 NA
Pre-Tax Margin
3/31/24 NA
12/31/23 -60,269.13
9/30/23 NA
Book Value
3/31/24 NA
12/31/23 1.31
9/30/23 1.61
Inventory Turnover
3/31/24 NA
12/31/23 NA
9/30/23 NA
Debt-to-Equity
3/31/24 NA
12/31/23 0.00
9/30/23 0.00
Debt to Capital
3/31/24 NA
12/31/23 0.05
9/30/23 0.00